This site contains promotional content intended for UK Healthcare Professionals and other relevant decision makers | Not a HCP? Visit our  Public Site.

Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below. 

  • Products
  • Therapy Areas
  • Resources
  • Events & Webinars
  • Learning Zone
  • Podcasts
Banner

Hot topics from ASCO-GU 2026: new data related to

NUBEQA (darolutamide)

Episode 2

Welcome to our

ASCO-GU
2026
 vlogcasts, where we present exclusive insights from two expert UK Consultant Oncologists on topics in prostate cancer treatment, filmed at the
ASCO-GU
2026
 in San Francisco.

Watch the 2-part short vlogcasts (approx. 5 mins each) recorded at ASCO‑GU 2026 with

Dr.
Giusepppe
Banna
 and
Dr. Angus Robinson,
 focused on hot topics from ASCO-GU – new data read-outs and insights on real‑world ARI use and preserving long-term QoL. 

The vlogcasts, PowerPoint presentation and 2-page summaries have been developed and funded by Bayer plc.

Episode 2 | Hot topics from ASCO-GU 2026 and new data for darolutamide

Insights from two expert UK Consultant Oncologists on topics in prostate cancer treatment.

Featuring:

  • Dr.
    Angus Robinson
         (Consultant Clinical Oncologist, University Hospitals Sussex NHS Foundation Trust - Prostate and Upper GI Cancer Specialist)
  • Dr.
    Giuseppe Banna
         (Consultant Medical Oncologist for Lung & Urology Tumours - Molecular Lead, Department of Oncology, Portsmouth Hospitals University NHS Trust)

NUBEQA (darolutamide) Prescribing Information

RELATED VIDEOS

ASCO-GU 2026 - Hot topics
Episode 1 | Hot topics from ASCO-GU 2026
NUBEQA® (darolutamide)
PP-NUB-GB-2962, March 2026
ASCO-GU 2026
ASCO‑GU 2026 Quick Data Digest Hub
NUBEQA® (darolutamide)
PP-NUB-GB-2955, March 2026

PP-NUB-GB-2963   |   March 2026